# US 2026/0092326 A1 · Circulating serum microrna biomarkers and methods for alzheimer's disease diagnosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092326 A1
- Document ID: US20260092326A1
- Status: Published application
- Kind: A1
- Application number: 19/280,334
- Filed: 2025-07-25
- Published: 2026-04-02
- Earliest claimed: 2017-06-19
- Assignees: St. John’s University
- Applicants: St. John’s University
- Inventors: Simon Geir Möller; Ketan Shirish Patil; Guido Werner Alves
- Web page: https://patentgrep.com/patent/US20260092326A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- G01N 2800/2821: Alzheimer
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Biomarkers and methods for identifying, verifying and confirming circulating serum-based microRNAs. The microRNAs (PARKmiRs) can be used to differentiate patient's suffering from Alzheimer's disease (AD) from non-AD patients.

## Claims

### Claim at position 1

1-51. (canceled)

### Claim 52

A method, comprising the steps of:
(a) providing a plasma sample from a human patient;
(b) detecting levels of SEQ ID NO: 22 and SEQ ID NO: 77 in the plasma sample;
(c) diagnosing the human patient with Alzheimer's disease when the levels of SEQ ID NO: 22 and SEQ ID NO: 77 in the plasma sample are decreased in comparison to the levels of SEQ ID NO: 22 and SEQ ID NO: 77 in control plasma samples obtained from healthy patients; and
(d) administering a cholinesterase inhibitor or an N-methyl-D-aspartate receptor antagonist to said human patient diagnosed with Alzheimer's disease.

### Claim 53 (depends on 52)

The method of claim 52, further comprising detecting the level of one or more miRNA selected from the group consisting of SEQ ID NOS: 2-21, 23, 24, 25-76 and 78-86 within said plasma sample.

### Claim 54 (depends on 52)

The method of claim 52, further comprising detecting the level of one or more miRNA selected from the group consisting of SEQ ID NOS: 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 24, 25, 26, 27, 28, 31, 30, 32, 33, 37, 38, 40, 42, 43, 44, 46, 47, 48, 49, 50, 51, 55, 56, 57, 58, 59, 60, 62, 63, 64, 67, 68, 71, 72, 74, 75, 78, 80, 81, 85 and 86 within said plasma sample.

### Claim 55 (depends on 52)

The method of claim 52, further comprising detecting the level of one or more miRNA selected from the group consisting of SEQ ID NOS: SEQ ID NOS: 4, 17, 18, 19, 20, 21, 23, 25, 26, 29, 34, 35, 36, 39, 45, 52, 53, 54, 61, 65, 66, 69, 70, 73, 76, 79, 82, 83 and 84 within said plasma sample.

### Claim 56 (depends on 52)

The method of claim 52, further comprising detecting the level of one or more miRNA selected from the group consisting of SEQ ID NOS: 15, 21, 24, 52, 54 and 55 within said plasma sample.

### Claim 57 (depends on 52)

The method of claim 52, further comprising detecting the level of one or more miRNA selected from the group consisting of SEQ ID NOS: 2-21, 23, 24, 25-76 and 78-86 within said plasma sample.

### Claim 58 (depends on 52)

The method of claim 52, further comprising detecting the level of one or more miRNA selected from the group consisting of SEQ ID NOS: 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 24, 25, 26, 27, 28, 31, 30, 32, 33, 37, 38, 40, 42, 43, 44, 46, 47, 48, 49, 50, 51, 55, 56, 57, 58, 59, 60, 62, 63, 64, 67, 68, 71, 72, 74, 75, 78, 80, 81, 85 and 86 within said plasma sample.

### Claim 59 (depends on 52)

The method of claim 52, further comprising detecting the level of one or more miRNA selected from the group consisting of SEQ ID NOS: 4, 17, 18, 19, 20, 21, 23, 25, 26, 29, 34, 35, 36, 39, 45, 52, 53, 54, 61, 65, 66, 69, 70, 73, 76, 79, 82, 83 and 84 within said plasma sample.

### Claim 60 (depends on 52)

The method of claim 52, further comprising detecting the level of one or more miRNA selected from the group consisting of SEQ ID NOS: 15, 21, 24, 52, 54 and 55 within said plasma sample.

### Claim 61 (depends on 53)

The method of claim 53, wherein said one or more miRNA comprises SEQ ID NO: 15.

### Claim 62 (depends on 53)

The method of claim 53, wherein said one or more miRNA comprises SEQ ID NO: 21.

### Claim 63 (depends on 53)

The method of claim 53, wherein said one or more miRNA comprises SEQ ID NO: 24.

### Claim 64 (depends on 53)

The method of claim 53, wherein said one or more miRNA comprises SEQ ID NO: 52.

### Claim 65 (depends on 53)

The method of claim 53, wherein said one or more miRNA comprises SEQ ID NO: 54.

### Claim 66 (depends on 53)

The method of claim 53, wherein said one or more miRNA comprises SEQ ID NO: 55.

### Claim 67 (depends on 52)

The method of claim 52, wherein said cholinesterase inhibitor is donepezil, galantamine or rivastigmine.

### Claim 68 (depends on 52)

The method of claim 52, wherein said N-methyl-D-aspartate receptor antagonist is memantine.

### Claim 69 (depends on 52)

The method of claim 52, wherein said one or more miRNA comprises SEQ ID NO: 25.

### Claim 70 (depends on 69)

The method of claim 69, further comprising detecting the level of one or more miRNA selected from the group consisting of SEQ ID NOS: 2-21, 23, 24, 26-76 and 78-86 within said plasma sample.

### Claim 71 (depends on 69)

The method of claim 69, further comprising detecting the level of at least one or more miRNA selected from the group consisting of SEQ ID NOS: 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 24, 26, 27, 28, 31, 30, 32, 33, 37, 38, 40, 42, 43, 44, 46, 47, 48, 49, 50, 51, 55, 56, 57, 58, 59, 60, 62, 63, 64, 67, 68, 71, 72, 74, 75, 78, 80, 81, 85 and 86 within said plasma sample.

### Claim 72 (depends on 69)

The method of claim 69, further comprising detecting the level of at least one or more miRNA selected from the group consisting of SEQ ID NOS: SEQ ID NOS: 4, 17, 18, 19, 20, 21, 23, 26, 29, 34, 35, 36, 39, 45, 52, 53, 54, 61, 65, 66, 69, 70, 73, 76, 79, 82, 83 and 84 within said plasma sample.

### Claim 73 (depends on 69)

The method of claim 69, further comprising detecting the level of at least one or more miRNA selected from the group consisting of SEQ ID NOS: 15, 21, 24, 52, 54 and 55 within said plasma sample.

### Claim 74 (depends on 69)

The method of claim 69, further comprising detecting the level of at least two or more miRNAs selected from the group consisting of SEQ ID NOS: 2-21, 23, 24, 26-76 and 78-86 within said plasma sample.

### Claim 75 (depends on 69)

The method of claim 69, further comprising detecting the level of at least two or more miRNAs selected from the group consisting of SEQ ID NOS: 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 24, 26, 27, 28, 31, 30, 32, 33, 37, 38, 40, 42, 43, 44, 46, 47, 48, 49, 50, 51, 55, 56, 57, 58, 59, 60, 62, 63, 64, 67, 68, 71, 72, 74, 75, 78, 80, 81, 85 and 86 within said plasma sample.

### Claim 76 (depends on 69)

The method of claim 69, further comprising detecting the level of at least two further miRNAs selected from the group consisting of SEQ ID NOS: 4, 17, 18, 19, 20, 21, 23, 26, 29, 34, 35, 36, 39, 45, 52, 53, 54, 61, 65, 66, 69, 70, 73, 76, 79, 82, 83 and 84 within said plasma sample.

### Claim 77 (depends on 69)

The method of claim 69, further comprising detecting the levels of at least two or more miRNAs selected from the group consisting of SEQ ID NOS: 15, 21, 24, 52, 54 and 55 within said plasma sample.

### Claim 78 (depends on 70)

The method of claim 70, wherein said at least one or more miRNA comprises SEQ ID NO: 15.

### Claim 79 (depends on 70)

The method of claim 70, wherein said at least one or more miRNA comprises SEQ ID NO: 21.

### Claim 80 (depends on 70)

The method of claim 70, wherein said at least one or more miRNA comprises SEQ ID NO: 24.

### Claim 81 (depends on 70)

The method of claim 70, wherein said at least one or more miRNA comprises SEQ ID NO: 52.

### Claim 82 (depends on 70)

The method of claim 70, wherein said at least one or more miRNA comprises SEQ ID NO: 54.

### Claim 83 (depends on 70)

The method of claim 70, wherein said at least one or more miRNA comprises SEQ ID NO: 55.

### Claim 84 (depends on 69)

The method of claim 69, wherein said cholinesterase inhibitor is donepezil, galantamine or rivastigmine.

### Claim 85 (depends on 69)

The method of claim 69, wherein said N-methyl-D-aspartate receptor antagonist is memantine.
